Investor presentation
Logotype for ImmuCell Corporation

ImmuCell (ICCC) Investor presentation summary

Event summary combining transcript, slides, and related documents.

Logotype for ImmuCell Corporation

Investor presentation summary

13 Nov, 2026

Market opportunity

  • Scours affects ~5 million U.S. calves annually and carries an estimated $800M–$1B yearly economic burden; it accounts for 30–40% of pre-weaning mortality in many production systems.

  • U.S. spending on scours preventatives reached $93M in 2025, up 14%; the presentation estimates a ~$200M U.S. TAM and a $1.4B global TAM across 20 markets.

  • In 2025, 55% of U.S. calves were untreated; calves using scours preventatives increased 10.4% since 2021 while total calf numbers declined 1.5%.

  • Rising calf values are strengthening the incentive to invest in calf health; newborn calf prices showed a 4–7x increase since 2024.

First Defense products and positioning

  • First Defense delivers targeted antibodies against E. coli, coronavirus and rotavirus, using a proprietary process to hyperimmunize cows and harvest colostrum antibodies.

  • Challenge trials reported 100% survival in a coronavirus challenge and 90% survival in an E. coli challenge; Tri-Shield plus colostrum provided 93% protection against severe rotavirus diarrhea.

  • First Defense neutralizing antibody levels were 3.3x–5.6x a market-leading competitor; hyperimmunized colostrum provides >2x the bioactive content of regular colostrum.

  • The portfolio targets distinct customer needs: Tri-Shield at $15/dose, Dual-Force at $8–$10.50/dose and First Defense Technology powder at $6.50/dose, based on average 2025 end-customer pricing.

  • U.S. category-spend share reached 34.1% YTD Jan–Sep 2026, versus 23.8% in 2021; treated-animal share was 17.0% YTD 2026.

Growth and manufacturing

  • First Defense production increased 73% from 2023 to 2026 YTD; 2026 priorities include better planning, less waste, higher utilization and optimized colostrum use.

  • An $8M capacity expansion includes $3.5M for freeze drying, expected complete H1 2027, and $4.5M for colostrum processing, expected complete H2 2027; investments are expected to triple capacity and cut production timelines to under one month.

  • Growth plans emphasize broader U.S. outreach, expansion into selected international markets and targeted product innovation; two U.S. sales hires since June 2026 increased customer reach by 60%.

  • International regulatory projects have started in target countries; the global opportunity is estimated at $1.4B across 20 markets.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from ImmuCell